Clinical Trials
20 trialsNCT06018337 2026-06-02
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
DualityBio Inc.
Phase 3 Active not recruiting
NCT06608927 2026-06-02
PRISM-1
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT06625320 2026-06-02
RASolute 302
Revolution Medicines, Inc.
Phase 3 Active not recruiting
NCT05374512 2026-05-15
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
AstraZeneca
Phase 3 Active not recruiting
NCT05382299 2026-04-06
ASCENT-03
Gilead Sciences
Phase 3 Active not recruiting
NCT06132958 2026-04-03
TroFuse-005
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04205812 2026-03-31
POD1UM-304
Incyte Corporation
Phase 3 Active not recruiting
NCT04895358 2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04494425 2026-03-04
DB-06
AstraZeneca
Phase 3 Active not recruiting
NCT03774732 2026-02-25
NIRVANA-LUNG
UNICANCER
Phase 3 Active not recruiting
NCT05502237 2026-01-30
STAR-121
Gilead Sciences
Phase 3 Active not recruiting
NCT06212752 2025-11-12
MK-3475A-D77
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03734029 2025-10-06
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Daiichi Sankyo
Phase 3 Active not recruiting
NCT05840211 2025-10-03
ASCENT-07
Gilead Sciences
Phase 3 Active not recruiting
NCT05382286 2025-09-18
ASCENT-04
Gilead Sciences
Phase 3 Active not recruiting
NCT05722015 2025-09-11
MK-3475A-D77
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06018883 2025-08-07
PTCA199-3
Fudan University
Phase 3 Active not recruiting
NCT05257408 2025-04-16
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Corcept Therapeutics
Phase 3 Active not recruiting
NCT04956692 2024-12-03
MK-3475-A86
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT02344472 2024-06-04
Detect V / CHEVENDO (Chemo vs. Endo)
University of Ulm
Phase 3 Active not recruiting